LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses 936,110 1,016,699
Preferred stock - -
Common stock 321,513 314,106
Additional paid-in capital 57,029,525 52,151,245
Accumulated deficit (50,888,121) (45,655,997)
Total stockholders' equity 6,462,917 6,809,354
Total liabilities and stockholders' equity $7,399,027 $7,826,053
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant
to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking statements
in this press release regarding potential ap
|SOURCE Neuralstem Inc.|
Copyright©2008 PR Newswire.
All rights reserved